Getting into the brain: Approaches to enhance brain drug delivery

CNS Drugs

Volumn 23, Issue 1, 2009, Pages 35-58

  Patel, Mayur M ^a   Goyal, Bhoomika R ^a   Bhadada, Shraddha V ^a   Bhatt, Jay S ^a   Amin, Avani F ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

Blood brain barrier; CNS disorders, treatment; Drug delivery systems; Infusion pumps; Intranasal; Intrathecal; Intraventricular; Lipid based delivery systems; Liposome encapsulation; Microspheres; Monoclonal antibody based delivery systems; Nanoparticles

Indexed keywords

4 AMINOBUTYRIC ACID; ALBUMIN; AMINO ACID TRANSPORTER; CARMUSTINE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORAMBUCIL; DOPAMINE; DOXORUBICIN; DRUG CARRIER; ESTRADIOL; GLUCOSE TRANSPORTER; IMMUNOGLOBULIN G; IRINOTECAN; LEVODOPA; LIPOSOME; MICROSPHERE; MONOCARBOXYLATE TRANSPORTER 1; MONOCLONAL ANTIBODY; MORPHINE; NANOCAPSULE; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NIFLUMIC ACID; NUCLEOBASE TRANSPORTER; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SOMATOMEDIN C; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

ACTIVE TRANSPORT; AREA UNDER THE CURVE; BIODEGRADABLE IMPLANT; BLOOD BRAIN BARRIER; COLLOID; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TRANSPORT; GENE THERAPY; HUMAN; INFUSION PUMP; LIPID SOLUBILITY; LIPOSOMAL DELIVERY; NANOPHARMACEUTICS; NONHUMAN; OSMOTIC STRESS; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS; TRANSPORT KINETICS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 57449121882     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200923010-00003     Document Type: Review

References (231)

1. Brightman MW. Morphology of blood-brain interfaces. Exp Eye Res 1977; 25 Suppl.: 1-25
2. Schlosshauer B. The blood-brain barrier: morphology, molecules, and neurothelin. Bioassays 1993 May; 15: 341-6
3. Ricci M, Blasi P, Giovagnoli S, et al. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 2006; 13: 1757-75
4. Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge: Cambridge University Press, 2001
5. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery: I. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999 Jan; 1: 55-68
6. MDL® comprehensive medicinal chemistry [online]. Available from URL: http://www.mdl.com/products/knowledge/medicinal_chem/index.jsp [Accessed 2008 Nov 26]
7. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000 Jul-Aug; 44: 235-49
8. Regier DA, Boyd JH, Burke Jr JD, et al. One-month prevalence of mental disorders in the United States: based on five epidemiologic catchment area sites. Arch Gen Psychiatry 1988; 45: 977-86
9. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007 Jan; 12: 54-61
10. Pardridge WM. Why is the global CNS pharmaceutical market so underpenetrated? Drug Discov Today 2002 Jan; 7: 5-7
11. Misra A, Ganesh S, Aliasgar S, et al. Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci 2003 May-Aug; 6: 252-73
12. Pardridge WM. Recent advances in blood brain-barrier transport. Annu Rev Pharmacol Toxicol 1988 Apr; 28: 25-39
13. Jamal T, Scherrmann JM, Rees AR, et al. Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm Sci Technol Today 2000 May; 3: 155-62
14. Greig NH. Drug delivery to the brain by blood-barrier: circumvention and drug modification. In: Neuwelt EA, editor. Implications of the blood-brain barrier and its manipulation. New York: Plenum Press, 1989: 311-67
15. Sawynok J. The therapeutic use of heroin: a review of the pharmacological literature. Can J Physiol Pharmacol 1986 Jan; 64: 1-6
16. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. J Clin Invest 1979 Jul; 64: 145-54
17. Lesniak MS. Novel advances in drug delivery to brain cancer. Technol Cancer Res Treat 2005 Aug; 4: 417-28
18. Albrecht KW, de Witt PC, Leenstra S, et al. High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin. J Neurooncol 2001 Jul; 53: 267-71
19. Koukourakis MI, Koukouraki S, Fezoulidis I, et al. High intratumoural accumulation of stealth liposomal doxorubicin (caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000 Nov; 83: 1281-6
20. Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001 Oct; 92: 1936-42
21. Lippens RJ. Liposomal daunorubicin (Daunoxome) in children with recurrent or progressive brain tumors. Pediatr Hematol Oncol 1999 Mar-Apr; 16: 131-9
22. Greig NH, Daly EM, Sweeney DJ, et al. Pharmacokinetics of chlorambucil-tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother Pharmacol 1990; 25: 320-5
23. Pardridge WM. Drug targeting to the brain. Pharm Res 2007 Sep; 24: 1733-44
24. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membrane Biol 1998 Oct; 165: 201-11
25. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003 Mar; 3: 90-105
26. Bodor N, Kaminski JJ. Prodrugs and site-specific chemical delivery systems. Annu Rep Med Chem 1987; 22: 303-13
27. Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 2000; 11 Suppl. 2: S15-27
28. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000; 2: E6
29. Bodor N. Drug targeting and retrometabolic drug design approaches. Adv Drug Deliv Rev 1994 Jun-Jul; 14: 157-66
30. Bodor N, Buchwald P. Drug targeting via retrometabolic approaches. Pharmacol Ther 1997 Oct-Dec; 76: 1-27
31. Somogyi G, Nishitani S, Nomi D, et al. Targeted drug delivery to the brain via phosphonate derivatives: I. Design, synthesis, and evaluation of an anionic chemical delivery system for testosterone. Int J Pharm 1998 May; 166: 15-26
32. Somogyi G, Buchwald P, Nomi D, et al. Targeted drug delivery to the brain via phosphonate derivatives: II. Anionic chemical delivery system for zidovudine (AZT). Int J Pharm 1998; 166: 27-35
33. Terasaki T, Tsuji A. Drug delivery to the brain utilizing blood-brain barrier transport systems. J Control Release 1994 Feb; 29: 163-9
34. Pardridge WM. New approaches to drug delivery through the blood-brain barrier. Trends Biotechnol 1994 Jun; 12: 239-45
35. Kang YS, Pardridge WM. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Pharm Res 1994 Sep; 11: 1257-64
36. Pardridge WM, Triguero D, Buciak JL, et al. Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. Endocrinology 1990 Feb; 126: 977-84
37. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am J Physiol 1971 Dec; 221: 1629-39
38. Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975 Jan; 292: 181-4
39. Cornford EM, Young D, Paxton JW, et al. Melphalan penetration of the blood-brain barrier via the neurtral amino acid transporter in tumor-bearing brain. Cancer Res 1992 Jan; 52: 138-43
40. Markovitz DC, Fernstrom JD. Diet and uptake of aldomet by the brain: competition with natural large neutral amino acids. Science 1977 Sep; 197: 1014-5
41. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002 Apr; 61: 729-37
42. Dalpiaz A, Pavan B, Vertuani S, et al. Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs. Eur J Pharm Sci 2005 Mar; 24: 259-69
43. Cornford EM, Oldendorf WH. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta 1975 Jun; 394: 211-9
44. Cornford EM, Braun LD, Oldendorf WH. Carrier mediated blood-brain barrier transport of choline and certain choline analogs. J Neurochem 1978 Feb; 30: 299-308
45. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier: studies with quantitative western blotting and in situ hybridization. J Biol Chem 1990 Oct; 265: 18035-40
46. Bonina FP, Arenare L, Palagiano F, et al. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J Pharm Sci 1999 May; 88: 561-7
47. Bonina FP, Arenare L, Ippolito R, et al. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int J Pharm 2000 Jul; 202: 79-88
48. Li JY, Boado RJ, Pardridge WM. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na+ nucleoside cotransporter CNT2. J Cereb Blood Flow Metab 2001 Aug; 21: 929-36
49. Pardridge WM, Yoshikawa T, Kang YS, et al. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Ther 1994 Jan; 268: 14-8
50. Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987 Sep; 420: 32-8
51. Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006; 83: 154-60
52. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001 Mar; 114: 168-72
53. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002 Apr; 81: 203-6
54. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 1990 Jun; 54: 1882-8
55. Shin SU, Friden P, Moran M, et al. Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci 1995 Mar; 92: 2820-4
56. Danielyan K, Ding BS, Gottstein C, et al. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther 2007 Jun; 321: 947-52
57. Kreuter J, et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995 Mar; 674: 171-4
58. Schroeder U, Sommerfeld P, Ulrich S, et al. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 1998 Nov; 87: 1305-7
59. Alyautdin RN, Petrov VE, Langer K, et al. Delivery of loperamide across the bloodbrain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997 Mar; 14: 325-8
60. Alyautdin RN, Tezikov EB, Ramge P, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998 Jan-Feb; 15: 67-74
61. Friese A, Seiller E, Quack G, et al. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000 Mar; 49: 103-9
62. Gulyaev AE, Gelperina SE, Skidan IN, et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999 Oct; 16: 1564-9
63. Kreuter J. Nanoparticlate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001 Mar; 47: 65-81
64. Kim HR, Andrieux K, Delomenie C, et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip® system. Electrophoresis 2007 Jul; 28: 2252-61
65. Kim HR, Andrieux K, Gil S, et al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007 Mar; 8: 793-9
66. Kim HR, Gill S, Andrieux K, et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 2007 Feb; 64: 356-64
67. Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008 Apr; 127: 97-109
68. Oyewumi MO, Yokel RA, Jay M, et al. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 2004 Mar; 95: 613-26
69. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992 Jun; 52: 3396-401
70. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995 Feb; 1233: 134-44
71. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003 Mar; 2: 214-21
72. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005 Jan; 2: 3-14
73. Cornford EM, Hyman S, Swartz BE. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab 1994 Jan; 14: 106-12
74. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998 Feb; 8: 84-7
75. Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000 April; 57: 679-86
76. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999 Sep; 285: 1569-72
77. Salahuddin TS, Johansson BB, Kalimo H, et al. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: an electron microscopic study. Acta Neuropathol 1988; 77: 5-13
78. Lossinsky AS, Vorbrodt AW, Wisniewski HM. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J Neurocytol 1995 Oct; 24: 795-806
79. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998 May; 42: 1083-100
80. Greenwood J, Luthert PJ, Pratt OE, et al. Hyperosmolar opening of the blood-brain barrier in the energy-depleted rat brain: part 1. Permeability studies. J Cereb Blood Flow Metab 1988 Feb; 8: 9-15
81. Doolittle ND, Petrillo A, Bell S, et al. Blood-brain barrier disruption for the treatment of malignant brain tumors: the National Program. J Neurosci Nurs 1998 Apr; 30: 81-90
82. Salahuddin TS, Johansson BB, Kalimo H, et al. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol Appl Neurobiol Neuropeptides 1988 Nov-Dec; 14: 467-82
83. Miller G. Drug targeting: breaking down barriers. Science 2002 Aug; 297: 1116-8
84. Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of the bradykinin analog, RMP-7. Neurosurgery 1996 Jul; 39: 125-33
85. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996 Mar; 2: 106-13
86. Emerich DF, Dean RL, Osborn C, et al. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 2001; 40: 105-23
87. Saija A, Princi P, Trombetta D, et al. Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat. Exp Brain Res 1997; 115: 546-51
88. Hanig JP, Morrison Jr JM, Krop S, et al. Ethanol enhancement of blood-brain barrier permeability to catecholamines in chicks. Eur J Pharmacol 1972 Apr; 18: 79-82
89. Kobiler D, Lustig S, Gozes Y, et al. Sodium dodecylsulphate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain. Brain Res 1989 Sep; 496: 314-6
90. Azmin MN, Stuart JF, Florence AT, et al. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 1985; 14: 238-42
91. Zhang Y, Miller DW. Pathways for drug delivery to the central nervous system. In: Wang B, Siahaan T, Soltero RA, editors. Drug delivery: principles and applications. New Jersey (NJ): Wiley Interscience, 2005: 29-56
92. Erdlenbruch B, Alipour M, Fricker G, et al. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharm 2003 Dec; 140: 1201-10
93. Erdlenbruch B, Jendrossek V, Eibl H, et al. Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats. Exp Brain Res 2000 Dec; 135: 417-22
94. Erdlenbruch B, Jendrossek V, Kugler W, et al. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother Pharmacol 2002 Oct; 50: 299-304
95. Erdlenbruch B, Schinkhof C, Kugler W, et al. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharm 2003 Jun; 139: 685-94
96. Pardridge WM, Kang YS, Buciak JL, et al. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 1995 Jun; 12: 807-16
97. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 1997 Oct; 100: 1804-12
98. Boado RJ, Zhang Y, Zhang Y, et al. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 2007 Aug; 97: 1376-86
99. Lee HJ, Engelhardt B, Lesley J, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 2000 Mar; 292: 1048-52
100. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 1991 Oct; 259: 66-70
101. Neuwelt EA, Rapoport SI. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc 1984 Feb; 43: 214-9
102. Suzuki T, Zhang Y, Zhang YF, et al. Imaging gene expression in regional brain ischemia in vivo with a targeted [111in]-antisense radiopharmaceutical. Mol Imaging 2004 Oct; 3: 356-63
103. Suzuki T, Wu D, Schlachetzki F, et al. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med 2004 Oct; 45: 1766-75
104. Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 2005 Jun; 313: 1075-81
105. Lee HJ, Zhang Y, Zhu C, et al. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab 2002 Feb; 22: 223-31
106. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 2001 Jan; 889: 49-56
107. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 2001 Jun; 32: 1378-84
108. Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A 1999 Jan; 96: 254-9
109. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res 1999 Dec; 59: 6159-63
110. Song BW, Vinters HV, Wu D, et al. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther 2002 May; 301: 605-10
111. Wu D, Pardridge WM. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther 1996 Oct; 279: 770-83
112. Zhang Y, Schlachetzki F, Zhang YF, et al. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther 2004 Apr; 15: 339-50
113. Zhang Y, Zhang YF, Bryant J, et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004 Jun; 10: 3667-77
114. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002 Jul; 6: 67-72
115. Boiardi A, Eoli M, Pozzi A, et al. Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Ital J Neurol Sci 1999 Feb; 20: 43-8
116. Morantz RA, Kimler BF, Vats TS, et al. Bleomycin and brain tumors: a review. J Neurooncol 1983; 1: 249-55
117. Patchell RA, Regine WF, Ashton P, et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 2002 Oct; 60: 37-42
118. Voulgaris S, Partheni M, Karamouzis M, et al. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002 Feb; 25: 60-4
119. Huang Y, Hayes RL, Wertheim S, et al. Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report. Crit Rev Oncol Hematol 2001 Jul-Aug; 39: 17-23
120. Boiardi A, Silvani A, Milanesi I, et al. Local immunotherapy (beta-ifn) and systemic chemotherapy in primary glial tumors. Ital J Neurol Sci 1991 Apr; 12: 163-8
121. Scheld WM. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. Rev Infect Dis 1989; 11 Suppl. 7: S1669-90
122. Giussani C, Carrabba G, Pluderi M, et al. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. Cancer Res 2003 May; 63: 2499-505
123. Grondin R, Zhang Z, Yi A, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002 Oct; 125: 2191-201
124. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003 May; 9: 589-95
125. Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005 Feb; 57: 298-302
126. Slevin JT, Gerhardt GA, Smith CD, et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005 Feb; 102: 216-22
127. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006 Mar; 59: 459-66
128. Nutt JG, Burchiel KJ, Comella CL. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003 Jan 14; 60: 69-73
129. Salvatore MF, Ai Y, Fischer B, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006 Dec; 202: 497-505
130. Dang W, Colvin OM, Brem H, et al. Covalent coupling of methotrexate dextran enhances the penetration of cytotoxicity into a tissue like matrix. Cancer Res 1994 Apr; 54: 1729-35
131. Batycky RP, Hanes J, Langer R, et al. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci 1997 Dec; 86: 1464-77
132. Benoit JP, Faisant N, Venier-Julienne MC, et al. Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release 2000 Mar; 65: 285-96
133. Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 2004 Jan; 100: 405-10
134. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices: I. Characterization, degradation, and release characteristics. J Biomed Mater Res 1985 Oct; 19: 941-55
135. Leong KW, D'Amore PD, Marletta M, et al. Bioerodible polyanhydrides as drug-carrier matrices: II. Biocompatibility and chemical reactivity. J Biomed Mater Res 1986 Jan; 20: 51-64
136. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001 Jul; 74: 63-7
137. Newcomb R, Abbruscato TJ, Singh T, et al. Bioavailability of ziconotide in brain: influx from blood, stability and diffusion. Peptides 2000 Apr; 21: 491-501
138. Elena B, Alexander VK. Polymers for CNS drug delivery. Pharm Tech. Epub 2007 May 1
139. Umezawa F, Eto Y. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem Biophys Res Comm 1988 Jun; 153: 1038-44
140. Aoki H, Kakinuma K, Morita K, et al. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hyperther 2004 Sep; 20: 595-605
141. Chekhonin VP, Zhirkov YA, Gurina OI, et al. PEGylated immunoliposomes directed against brain astrocytes. Drug Deliv 2005 Jan-Feb; 12: 1-6
142. Pardridge WM. Tyrosine hydroxylase replacement in experimental parkinson's disease with transvascular gene therapy. NeuroRx 2005 Jan; 2: 129-38
143. Voinea M, Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med 2002 Oct-Dec; 6: 465-74
144. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 2006 Mar; 66: 2801-6
145. Schmidt J, Metselaar JM, Wauben MH, et al. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003; 126: 1895-904
146. Garcia-Garcia E, Andrieux K, Gil S, et al. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 2005 May; 298: 274-92
147. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: rationale for combination with radiotherapy. Acta Oncol 2000; 39: 207-11
148. Hau P, Fabel K, Baumgart U, et al. PEGylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004 Mar; 100: 1199-207
149. Sugawa N, Ueda S, Nakagawa Y, et al. An antisense EGFR oligonucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neuro-Oncol 1998 Sep; 39: 237-44
150. Omori N, Maruyama K, Jin G, et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 2003 Apr; 25: 275-9
151. Schmidt J, Metselaar JM, Gold R. Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. J Histochem Cytochem 2003 Sep; 51: 1241-4
152. Yoshida J, Mizuno M, Fujii M, et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 2004 Jan; 15: 77-86
153. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000 Jul; 182: 274-82
154. Mizuno M, Ryuke Y, Yoshida J. Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models. Cancer Gene Ther 2002 Oct; 9: 825-9
155. Shi N, Zhang Y, Zhu C, et al. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A 2001 Oct; 98: 12754-9
156. Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002 Feb; 10: 73-9
157. Wu D, Song BW, Vinters HV, et al. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target 2002 May; 10: 239-45
158. Wu D, Boado RJ, Pardridge WM. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther 1996 Jan; 276: 206-11
159. Gosk S, Vermehren C, Storm G, et al. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 2004 Nov; 24: 1193-204
160. da Cruz MT, Simoes S, de Lima MC. Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp Neurol 2004 May; 187: 65-75
161. Matsuo H, Okamura T, Chen J, et al. Efficient introduction of macromolecules and oligonucleotides into brain capillary endothelial cells using HVJ-liposomes. J Drug Target 2000; 8: 207-16
162. Zhang Y, Zhang YF, Bryant J, et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004 Jun; 10: 3667-77
163. Tosi G, Costantino L, Ruozi B, et al. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008 Feb; 5: 155-74
164. Calvo P, Gouritin B, Villarroya H, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 2002 Apr; 15: 1317-26
165. Darius J, Meyer FP, Sabel BA, et al. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol 2000; 562: 1043-7
166. Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004 May; 109: 759-67
167. Cui Z, Lockman PR, Atwood CS, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm 2005 Feb; 59: 263-72
168. Costantino L, Gandolfi F, Tosi G, et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 2005 Nov; 108: 84-96
169. Aktas Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chem 2005 Nov-Dec; 16: 1503-11
170. Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release 2007 Sep; 122: 1-9
171. Petri B, Bootz A, Khalansky A, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 2007 Jan; 117: 51-8
172. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Delivery Rev 2007 Jul; 59: 454-77
173. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin rationale for use in solid tumours. Drugs 1997; 54 Suppl. 4: 15-21
174. Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006 Jan; 307: 93-102
175. Yang S, Zhu J, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999 May; 16: 751-7
176. Zara GP, Cavalli R, Fundarò A, et al. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 1999 Sep; 40: 281-6
177. Podio V, Zara GP, Carazzonet M, et al. Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. J Pharm Pharmacol 2000 Sep; 52: 1057-63
178. Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999 Jun; 59: 299-307
179. Fundarò A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000 Oct; 42: 337-43
180. Koziara JM, Lockman PR, Allen DD, et al. In situ blood-brain barrier transport of nanoparticles. Pharm Res 2003 Nov; 20: 1772-8
181. Koziara JM, Lockman PR, Allen DD, et al. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004 Sep; 99: 259-69
182. Lockman PR, Koziara J, Roder KE, et al. In vivo and in vitro assessment of baseline blood brain barrier parameters in the presence of novel nanoparticles. Pharm Res 2003 May; 20: 705-13
183. Peira E, Marzola P, Podio V, et al. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 2003 Jan; 11: 19-24
184. Yang C, Chang CH, Tsai PJ, et al. Nanoparticle-based in vivo investigation on blood-brain barrier permeability following ischemia and reperfusion. Anal Chem 2004 Aug; 76: 4465-71
185. Yumi T, Kazuhito T, Mana N, et al. Development of bionano-capsules targeting brain tumors. J Control Release 2007 Sep; 122: 159-64
186. Vinogradov SV, Batrakova EV, Kabanov AV. Poly(ethylene glycol)- polyethyleneimine nanogel particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf B: Biointerfaces 1999 Nov; 16: 291-304
187. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002 Jan; 54: 135-47
188. Vinogradov SV, Kohli E, Zeman AD. Cross-linked polymeric nanogel formulations of 5′-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. Mol Pharm 2005 Nov-Dec; 2: 449-61
189. Vinogradov SV, Zeman AD, Batrakova EV. Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Release 2005 Sep; 107: 143-57
190. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 2004 Jan-Feb; 15: 50-60
191. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Design 2004; 10: 1355-63
192. Madrid Y, Langer LF, Brem H, et al. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol 1991; 22: 299-324
193. Leigh K, Elisevich K, Rogers KA. Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. J Neurosurg 1994 Aug; 81: 272-83
194. Lal B, Indurti RR, Couraud PO, et al. Endothelial cell implantation and survival within experimental gliomas. Proc Natl Acad Sci U S A 1994 Oct; 91: 9695-9
195. Snyder EY, Senut MC. The use of non neuronal cells for gene delivery. Neurobiol Dis 1997; 4: 69-102
196. Yurek DM, Sladek Jr JR. Dopamine cell replacement: Parkinson's disease. Annu Rev Neurosci 1990; 13: 415-40
197. Santini Jr JT, Cima MJ, Langer R. A controlled-release microchip. Nature 1999 Jan; 397: 335-8
198. Thorne RG, Emory CR, Ala TA, et al. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995 Sep; 692: 278-82
199. Thorne RG, Frey II WH. Delivery of neurotropic factore to the central nervous system: pharmacokinetic consideration. Clin Pharmacokinet 2001; 40: 907-46
200. Born J, Lange T, Kern W. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002 Jun; 5: 514-6
201. Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-96
202. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release 2003 Feb; 87: 187-98
203. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000 Jul; 11: 1-18
204. Quay SC. Successful delivery of apomorphine to the brain following intranasal administration demonstrated in clinical study [online]. Available from URL: http://www.riskworld.com/PressRel/2001/01q3/PR01a006.htm [Accessed 2008 Nov 26]
205. Fehm HL, Perras B, Smolnik R, et al. Manipulating neuropeptidergic pathways in humans: a novel approach to neuropharmacology. Eur J Pharmacol 2000 Sep; 405: 43-54
206. Perras B, Pannenborg H, Marshall L, et al. Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin. J Clin Psychopharmacol 1999 Feb; 19: 28-36
207. Perras B, Marshall L, Kohler G, et al. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuro-endocrinology 1999 Oct; 24: 743-57
208. Dahlin M, Bergman U, Jansson B, et al. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 2000 Jun; 17: 737-42
209. Ulrika W, Elena P, Björn J, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005 Apr; 24: 565-73
210. Merkus P. Nose to brain: management forum nasal drug delivery symposium. 2001 Mar 26-27; London
211. Xiaomei W, Haibing H, Wei L, et al. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm 2006 Jul; 317: 40-6
212. Jian C, Xiaomei W, Juan W. Evaluation of brain targeting for the nasal delivery of ergoloid mesylate by the micro dialysis methods in the rats. Eur J Pharm Biopharm 2008 Mar; 68: 694-700
213. Gao X, Tao W, Lu W, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intra nasal administration. Biomaterials 2006 Jun; 27: 3482-90
214. Gao X, Wu B, Zhang Q, et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with the wheat germ agglutinin following intranasal administration. J Control Release 2007 Aug; 121: 156-67
215. Gao X, Chen J, Tao W, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm 2007 Aug; 340: 207-15
216. Illum L. Nasal drug delivery: new development strategies. Drug Discov Today 2002; 7: 1184-9
217. Krauze MT, Saito R, Noble C, et al. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol 2005; 196: 104-11
218. Debinski W, Gibo DM, Puri RK. Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13. Int J Cancer 1998; 76: 547-51
219. Debinski W, Obiri NI, Powers SK, et al. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995 Nov; 1: 1253-8
220. Debinski W, Gibo DM, Hulet SW, et al. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999 May; 5: 985-90
221. Debinski W, Slagle B, Gibo DM, et al. Expression of a restrictive receptor for Interleukin 13 is associated with glial transformation. J Neurooncol 2000 Jun; 48: 103-11
222. Kunwar S. Convection enhanced delivery of I13-PE38QQR for treatment of recurrent malignant glioma: presentation of inter-im findings from ongoing phase 1 studies. Acta Neurochir 2003; 88 Suppl.: 105-11
223. Hall WA, Godal A, Juell S, et al. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 1992 May; 76: 838-44
224. Martell LA, Agrawal A, Ross DA. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 1993 Mar; 53: 1348-53
225. Buchwald P, Bodor N. A simple, predictive, structure- based skin permeability model. J Pharm Pharmacol 2001 Aug; 53: 1087-98
226. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 1995 May; 680: 196-206
227. Rietman JS, Geertzen JH. Efficacy of intrathecal baclofen delivery in the management of severe spasticity in upper motor neuron syndrome. Acta Neurotic Suppl 2007; 97 (Pt 1): 205-11
228. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996 Sep; 85: 458-67
229. Varelas PN, Rehman M, Pierce W, et al. Vancomycin-resistant enterococcal meningitis treated with intrathecal streptomycin. Clin Neurol Neurosurg 2008 Apr; 110 (4): 376-80
230. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975 Oct; 195: 73-83
231. Huang TY, Arita N, Hayakawa T, et al. ACNU, MTX and 5-FU penetration of rat brain tissue and tumors. J Neurooncol 1999; 45: 9-17